AKOYA BIOSCIENCES INC (AKYA) Stock News
NASDAQ:AKYA - Nasdaq - US00974H1041 - Common Stock - Currency: USD
AKYA Latest News, Press Releases and Analysis
Akoya Biosciences Unveils Strategic Product Roadmap, Powered by the New IO60 and Upcoming Neurobiology Panels
Akoya Biosciences Unveils Strategic Product Roadmap, Powered by the New IO60 and Upcoming Neurobiology Panels
Rapid menu expansion with new high-plex human and mouse neurobiology panels joining the recently launched Human IO60 and Mouse FFPE IO Panels The new...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SSTK, AKYA, POAI on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates SSTK, ACCD, ESSA, AKYA on Behalf of Shareholders
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates ESSA, AKYA, CCNE, QTRX on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
AKYA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Akoya Biosciences, Inc. Is Fair to Shareholders
Quanterix Agrees to Buy Life Sciences Firm Akoya Biosciences
Quanterix Corp. agreed to acquire life sciences peer Akoya Biosciences Inc. in an all-stock deal, combining two companies that detect diseases at different stages of progression.
Quanterix Is Close to All-Stock Deal for Akoya Bioscience
Quanterix Corp. is in advanced talks to acquire life sciences peer Akoya Biosciences Inc. in an all-stock deal, according to people familiar with the matter, potentially combining two companies that detect diseases at different stages of progression.
Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions
Akoya expands clinical test menu, exclusively licensing the global rights to develop and commercialize NeraCare's Immunoprint test for prognostication of disease recurrence in early-stage melanoma patients to better guide treatment decisions and potentially increase access to life saving therapies for those patients at high risk of developing metastatic disease
Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions
Akoya expands clinical test menu, exclusively licensing the global rights to develop and commercialize NeraCare's Immunoprint test for prognostication of...
Nature Methods Names Spatial Proteomics "Method of the Year 2024" — Akoya Biosciences Celebrates Industry Milestone
Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend
/PRNewswire/ -- USA News Group News Commentary – Despite death rates for some cancers being on the decline, there is a global surge in cancer cases among...
Akoya Biosciences Reports Third Quarter 2024 Financial Results
Akoya Biosciences Reports Third Quarter 2024 Financial Results
MARLBOROUGH, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its...
Akoya Biosciences Unveils a New Era in Spatial Content Innovation with the PhenoCode™ Discovery IO60 and Mouse FFPE IO Panel
Akoya Biosciences Unveils a New Era in Spatial Content Innovation with the PhenoCode™ Discovery IO60 and Mouse FFPE IO Panel
Pre-orders now available; early access available for select strategic partners for the PhenoCode IO60 panel – The Fastest Ultrahigh-plex Panel for...
Akoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024
Akoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024
MARLBOROUGH, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced...
Akoya’s Leading Spatial Proteomics Platforms Selected for Use by Ground-Breaking UK-Based MANIFEST Consortium to Revolutionize Cancer Immunotherapy
Akoya’s Leading Spatial Proteomics Platforms Selected for Use by Ground-Breaking UK-Based MANIFEST Consortium to Revolutionize Cancer Immunotherapy
Consortium includes top universities, hospitals and industry partners, led by the Francis Crick Institute and The Royal Marsden NHS Foundation Trust ...
Akoya Biosciences Announces Scott Mendel as Chairman of the Board of Directors
Akoya Biosciences Announces Scott Mendel as Chairman of the Board of Directors
MARLBOROUGH, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), the Spatial Biology Company®, today announced...
AKYA Stock Earnings: Akoya Biosciences Meets EPS, Misses Revenue for Q2 2024
AKYA stock results show that Akoya Biosciences met analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
AKYA Stock Earnings: Akoya Biosciences Meets EPS, Misses Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Akoya Biosciences (NASDAQ:AKYA) just reported results for the second quarter of...
Akoya Biosciences Reports Second Quarter 2024 Financial Results
Akoya Biosciences Reports Second Quarter 2024 Financial Results
MARLBOROUGH, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its...
Akoya Biosciences to Report Second Quarter 2024 Financial Results on August 5, 2024, and Participate at Two Upcoming Investor Conferences
Akoya Biosciences to Report Second Quarter 2024 Financial Results on August 5, 2024, and Participate at Two Upcoming Investor Conferences
MARLBOROUGH, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced...